CD19 targeted CAR-T cells

Phase 1Cell therapy

CChongqing Precision Biotech Co., Ltd

CD19 targeted CAR-T cells is one of 108 biologic programs targeting Lymphoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

107

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

LeukemiaActive, not recruiting

Autoimmune DiseaseActive, not recruiting

LymphomaPhase 1/Phase 2

Active, not recruiting

LeukemiaPreclinical

Active, not recruiting

Autoimmune DiseasePhase 1

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 2

Velban

EEastern Cooperative Oncology Group

Preclinical

15 3

Oncaspar

SServier

Preclinical

15 4

Zofran

Novartis

Preclinical

2 5

Norvir

AbbVie

Preclinical

1 6

Tafasitamab

Incyte

Preclinical

7 7

Decadron

QQuince Therapeutics S.p.A.

Systemic Therapy

1 9

PEG-Intron

Merck & Co.

Preclinical

1 10

CD19 targeted CAR-T cells

CChongqing Precision Biotech Co., Ltd

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Recruiting

Autoimmune Disease

NCT06056921

Q3 2027

Phase 1/2Recruiting

Relapsed/refractory

NCT04781634

Clinical

Trials by Indication[1]

Lymphoma4 trials

Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Diffuse Large B Cell Lymphoma

Unknown status·SSinobioway Cell Therapy Co., Ltd.·N/A·NCT02728882·24 enrolled

CAR-T Treatment for Relapse / Refractory Type Safety and Effectiveness of Lymphoma

Unknown status·SSinobioway Cell Therapy Co., Ltd.·N/A·NCT03488160·6 enrolled

a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma

Unknown status·CChongqing Precision Biotech Co., Ltd·Phase 1/2·NCT04782193·40 enrolled

Show 1 more trial

Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma

Unknown status·KKecellitics Biotech Company Ltd·Phase 1/2·NCT05651100·50 enrolled

Leukemia3 trials

CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma

Unknown status·CChongqing Precision Biotech Co., Ltd·Phase 1/2·NCT04649983·40 enrolled

Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma

Unknown status·CChongqing Precision Biotech Co., Ltd·Phase 1/2·NCT04648475·40 enrolled

Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Acute Non T Lymphocyte Leukemia

Unknown status·SSinobioway Cell Therapy Co., Ltd.·N/A·NCT02735291·72 enrolled

Autoimmune Disease1 trial

Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease

Recruiting·CChongqing Precision Biotech Co., Ltd·Phase 1·NCT06056921·24 enrolled

Autologous Stem Cell Transplantation1 trial

CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell Transplantation

Unknown status·QQingdao Central Hospital·N/A·NCT03564977·20 enrolled

Relapsed/Refractory1 trial

a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL

Recruiting·CChongqing Precision Biotech Co., Ltd·Phase 1/2·NCT04781634·40 enrolled

1 more indication

Relapsed or Refractory1 trial

CD19 and CD22 Dual-targeted CAR-T Cells for Relapsed or Refractory B-NHL

Unknown status·XXinqiao Hospital of Chongqing·Phase 1·NCT04303247·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for CD19 targeted CAR-T cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CD19 targeted CAR-T cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CD19 targeted CAR-T cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Chongqing Precision Biotech Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: CChongqing Precision Biotech Co., Ltd

CD19 targeted CAR-T cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q3 2027

Trials by Indication[1]

Lymphoma4 trials

Leukemia3 trials

Autoimmune Disease1 trial

Autologous Stem Cell Transplantation1 trial

Relapsed/Refractory1 trial

Relapsed or Refractory1 trial

References

Drug Info

Quick Facts

Related News